# First Observation of Left-Handed Helical Conformation in a Dehydro Peptide Containing Two L-Val Residues. Crystal and Solution Structure of Boc-L-Val- $\Delta$ Phe- $\Delta$ Phe- $\Delta$ Phe-L-Val-OMe ${ }^{\dagger, \perp}$ 

R. M. Jain, ${ }^{\ddagger}$ K. R. Rajashankar, ${ }^{\S}$ S. Ramakumar, ${ }^{\S}$ and V. S. Chauhan** ${ }^{*}$<br>Contribution from the International Centre for Genetic Engineering and Biotechnology, Aruna Asaf Ali Marg, New Delhi-110067, India, and Department of Physics, Indian Institute of Science, Bangalore-560012, India

Received May 2, $1996^{*}$


#### Abstract

The solution and solid structure of Boc-L-Val- $\Delta$ Phe- $\Delta$ Phe- $\Delta$ Phe-L-Val-OMe, containing three consecutive $\Delta$ Phe residues, have been determined by X-ray diffraction, nuclear magnetic resonance, and circular dichroism methods. The crystals grown from aqueous methanol are orthorhombic, space group $P 2_{1} 2_{1} 2_{1}, a=11.624(2), b=17.248(2)$, $c=21.532 \AA, V=4216(1) \AA^{3}, Z=4$. In the solid state, the peptide exhibits a left-handed $3_{10}$-helical conformation, in spite of the presence of two L-Val residues. NMR and CD studies in different solvents also support the crystal structure data, suggesting that the solid state structure is maintained in solution as well. This is the first report of a dehydropeptide containing three consecutive $\Delta$ Phe residues and exhibiting left-handed $3_{10}$-helical conformation, which demonstrates the remarkable conformational consequences produced by consecutive occurrence of $\Delta$ Phe residues in a peptide.


## Introduction

Peptide and protein mimicry aims to transfer some of the complex structural and functional properties of this class of bioactive molecules to simplified, synthetically accessible compounds. To this end, substitution with $\alpha, \beta$-dehydroamino acid ( $\Delta$ a.a) comes in use for producing well defined structural motifs. ${ }^{1}$ In the last few years, a large body of studies has been devoted in order to determine the likely conformational consequences of the presence of dehydro residues, especially $\alpha, \beta$ dehydrophenylalanine ( $\Delta \mathrm{Phe}$ ). Incorporation of $\Delta$ Phe in bioactive peptides confers increased resistance to enzymatic degradation ${ }^{2}$ as well as altered bioactivity. ${ }^{3}$ Determination of the crystal and molecular structure of many $\Delta$ Phe containing peptides has provided evidence that $\Delta \mathrm{Phe}$ is strong inducer of $\beta$-bend ${ }^{4}$ in short sequences and $3_{10}$-helical conformation in long sequences. ${ }^{5}$ A great deal of NMR studies has also been performed, which confirms the presence of ordered structure for dehydro peptides ${ }^{5 b m t}$ in solution as well. In this regard the behavior of $\Delta$ Phe is somewhat similar to that of $\alpha$-amino isobutyric acid (Aib), a highly helicogenic non-protein amino acid residue. ${ }^{6}$

[^0]The versatility of $\Delta$ Phe residues was demonstrated in a dehydropentapeptide containing two $\Delta$ Phe residues wherein a novel $\beta$-bend ribbon conformation was observed ${ }^{50}$ as well as in another pentapeptide having a single $\Delta$ Phe residue exhibiting an $\alpha$-helical conformation. ${ }^{5 s}$ However, there is relatively less information on peptide containing consecutive $\Delta$ Phe residues; there are only three crystal structure reports of dehydrotripeptides containing two consecutive $\Delta$ Phe residues. ${ }^{5 h-j}$ In these peptides either an extended structure or $3_{10}$-helical conformations with both left-handed and right-handed screw sense are observed. It is of much interest to determine the behavior of more than two consecutive $\Delta$ Phe residues in peptides. Here, we report for the first time the crystal and solution structure of a peptide containing three consecutive $\Delta$ Phe residues viz. Boc-L-Val$\Delta$ Phe- $\Delta$ Phe- $\Delta$ Phe-L-Val-OMe (1). The peptide exhibits a lefthanded $3_{10}$-helical conformation in spite of the presence of two
(5) (a) Ajo, D.; Casarin, M.; Granozzi, G. J. Mol. Struct. 1982, 86, 297. (b) Bharadwaj, A.; Jaswal, A.; Chauhan, V. S. Tetrahedron 1992, 48, 2691. (c) Ciszak, E.; Pietrzynski, G.; Rzeszotarska, B. Int. J. Peptide Protein Res. 1992, 39, 218. (d) Gupta, A.; Chauhan, V. S. Int. J. Peptide Protein Res. 1993, 41, 421. (e) Busetti, V.; Crisma, M.; Toniolo, C.; Salvadori, S.; Balboni, G. Int. J. Biol. Macromol. 1992, 14, 23. (f) Bach, II, A. C.; Gierasch, L. M. Biopolymers 1986, 25, S175. (g) Narula, P.; Khandelwal, B.; Singh, T. P. Biopolymers 1991, 31, 987. (h) Pieroni, O.; Montagnoli, G.; Fissi, A.; Merlino, S.; Ciardelli, F. J. Am. Chem. Soc. 1975, 97, 6820. (i) Pieroni, O.; Fissi, A.; Merlino, S.; Ciardelli, F. Isr. J. Chem. 1976/77, 15, 22. (j) Tuzi, A.; Ciajolo, M. R.; Guarino, G.; Temussi, P. A.; Fissi, A.; Pieroni, O. Biopolymers 1993, 33, 1111. (k) Chauhan, V. S.; Bhandary, K. K. Int. J. Peptide Protein Res. 1992, 39, 223. (1) Pieroni, O.; Fissi, A.; Pratesi, C.; Temussi, P. A.; Ciardelli, F. Biopolymers 1993, 33, 1. (m) Bhandary, K. K.; Chauhan, V. S. Biopolymers 1993, 33, 209. (n) Rajashankar, K. R.; Ramakumar, S.; Chauhan, V. S. J. Am. Chem. Soc. 1992, 114, 9225. (o) Rajashankar, K. R.; Ramakumar, S.; Mal, T. K.; Chauhan,V. S. Angew. Chem., Int. Ed. Engl. 1994, 33, 970. (p) Rajashankar, K. R.; Ramakumar, S.; Mal, T. K.; Jain, R. M.; Chauhan, V. S. Biopolymers 1995, 35, 141. (q) Ciajolo, M. R.; Tuzi, A.; Pratesi, C. R.; Fissi, A.; Pieroni, O. Biopolymers 1990, 30, 911. (r) Ciajolo, M. R.; Tuzi, A.; Pratesi, C. R.; Fissi, A.; Pieroni, O. Int. J. Peptide Protein Res. 1991, 38, 539. (s) Rajashankar, K. R.; Ramakumar, S.; Jain, R. M.; Chauhan, V. S. J. Am. Chem. Soc. 1995, 117, 10129. (t) Rajashankar, K. R.; Ramakumar, S.; Jain, R. M.; Chauhan, V. S. J. Am. Chem. Soc. 1995, 117, 11773.
(6) (a) Karle, I. L.; Balaram, P. Biochemistry 1990, 29, 6747. (b) Toniolo, C.; Benedetti, E. Macromolecules 1991, 24, 4004.

L-Val residues. This demonstrates the remarkable conformational consequences produced by consecutive occurrence of $\Delta$ Phe residues in peptides.

## Experimental Procedures

Synthesis. Boc-Val-dL-Phe( $\boldsymbol{\beta}$-OH)-OH (2). To a solution of Boc-Val-OH ( $4.0 \mathrm{~g}, 18.43 \mathrm{mmol}$ ) in tetrahydrofuran ( 20 mL ) at $-10^{\circ} \mathrm{C}$, N -methylmorpholine ( $2.02 \mathrm{~mL}, 18.43 \mathrm{mmol}$ ) and isobutylchloroformate $(2.4 \mathrm{~mL}, 18.43 \mathrm{mmol})$ were added. The reaction mixture was stirred for 10 min . A precooled solution of dL-Phe $(\beta-\mathrm{OH})-\mathrm{OH}(3.34 \mathrm{~g}, 18.43$ mmol ) in aqueous $\mathrm{NaOH}(1 \mathrm{~N}, 18.4 \mathrm{~mL}, 18.43 \mathrm{mmol})$ was added to the reaction mixture. The mixture was stirred for 2 h at $0^{\circ} \mathrm{C}$ and overnight at room temperature. After completion (checked by TLC) reaction mixture was concentrated in vасиo, and residue was taken in water. Maintaining the pH of the aqueous layer to $8-9$, it was washed once with ethyl acetate. Aqueous layer was then acidified with solid citric acid to pH 3 , and the resulting oil was extracted three to four times with ethyl acetate. Combined organic extract was washed with saturated NaCl , dried over sodium sulfate, and evaporated to give $\mathbf{2}$ as an oily product (yield $=80 \%$ ). $R_{f}\left[\mathrm{CHCl}_{3}-\mathrm{CH}_{3} \mathrm{OH}(9: 1)\right]=0.5 ;{ }^{1} \mathrm{H}$ NMR ( $\left.270 \mathrm{MHz}, \mathrm{CDCl}_{3}\right) \delta(\mathrm{ppm}): 7.2(5 \mathrm{H}, \mathrm{m}$, aromatic protons); 6.6 ( 1 H , br, NH dL-Phe $(\beta-\mathrm{OH})$ ); $5.2(1 \mathrm{H}, \mathrm{br}, \mathrm{NH} \mathrm{Val}) ; 4.8\left(1 \mathrm{H}, \mathrm{br}, \mathrm{C}^{\alpha} \mathrm{H}\right.$ DL-Phe( $\beta-\mathrm{OH}$ )); $4.1\left(1 \mathrm{H}, \mathrm{m}, \mathrm{C}^{\alpha} \mathrm{H}\right.$ Val); $1.4\left(9 \mathrm{H}, \mathrm{s}, 3 \times \mathrm{CH}_{3} \mathrm{Boc}\right)$; $1.0\left(6 \mathrm{H}, \mathrm{d}, 2 \times \mathrm{CH}_{3} \mathrm{Val}\right)$.

Boc-Val- $\mathbf{\Delta P h e - A z l a c t o n e ~ ( 3 ) . ~ A ~ s o l u t i o n ~ o f ~ d i p e p t i d e ~} 2(6.20 \mathrm{~g}$, 16.31 mmol ) in acetic anhydride ( 40 mL ) and anhydrous sodium acetate $(1.734 \mathrm{~g}, 21.15 \mathrm{mmol})$ was stirred for 20 h at room temperature. The reaction mixture was then poured over crushed ice, and the precipitate was filtered, washed with $5 \% \mathrm{NaHCO}_{3}$ and water, and dried under vacuum. The azlactone was crystallized from acetone/water to get the pure compound (yield $=75 \%$ ). $\mathrm{Mp}=114-115{ }^{\circ} \mathrm{C} ; R_{f}\left[\mathrm{CHCl}_{3}-\mathrm{CH}_{3}-\right.$ $\mathrm{OH}(9: 1)]=0.8, R_{f}\left[\right.$ butanol-acetic acid $\left.-\mathrm{H}_{2} \mathrm{O}(4: 1: 1)\right]=0.9 ; R_{f}$ $\left[\mathrm{CHCl}_{3}-\mathrm{CH}_{3} \mathrm{OH}(9: 1)\right]=0.5 ;{ }^{1} \mathrm{HNMR}\left(270 \mathrm{MHz}, \mathrm{CDCl}_{3}\right) \delta(\mathrm{ppm})$ : $7.3-7.1(5 \mathrm{H}, \mathrm{m}$, aromatic protons); $5.1(1 \mathrm{H}, \mathrm{br}, \mathrm{NH} \mathrm{Val}) ; 4.1(1 \mathrm{H}, \mathrm{br}$, $\mathrm{C}^{\alpha} \mathrm{H}$ Val); 2.1 ( $1 \mathrm{H}, \mathrm{m}, \mathrm{C}^{\beta} \mathrm{H}$ Val); 1.35 ( $9 \mathrm{H}, \mathrm{s}, 3 \times \mathrm{CH}_{3} \mathrm{Boc}$ ); $1.0(6 \mathrm{H}$, d, $\left.2 \times \mathrm{CH}_{3} \mathrm{Val}\right)$.

Boc-Val- $\mathbf{\Delta P h e}$ - $\boldsymbol{\Delta}$ Phe- $\mathbf{\Delta P h e - V a l - O M e ~ ( 1 ) . ~ D L - P h e ~ ( ~} \beta$-OH)-OH (1.4 g, 7.54 mmol ) dissolved in $1 \mathrm{~N} \mathrm{NaOH}(12 \mathrm{~mL})$ and acetone $(20 \mathrm{~mL})$ was added to a solution of azlactone $\mathbf{3}(2 \mathrm{~g}, 5.8 \mathrm{mmol})$ in acetone, and the reaction mixture was stirred at room temperature. After 24 h , the reaction mixture was neutralized by adding $1 \mathrm{~N} \mathrm{HCl}(12 \mathrm{~mL})$. Solvent was removed under vacuum, and the residue was dissolved in ethyl acetate, washed with water, dried over sodium sulfate, and evaporated to yield Boc-Val- $\Delta$ Phe-dL-Phe $(\beta-\mathrm{OH})-\mathrm{OH}$ (4) (single spot on TLC). Tripeptide $\mathbf{4}$ was used in the next step with no further purification and $(2.8 \mathrm{~g}, 5.3 \mathrm{mmol})$ reacted with anhydrous sodium acetate $(0.48 \mathrm{~g}, 5.88$ mmol ) and acetic anhydride ( 25 mL ) for 48 h at room temperature. The reaction was worked up as before to yield Boc-Val- $\Delta$ Phe- $\Delta$ Pheazlactone (5) in pure form. Peptide $5(2 \mathrm{~g}, 4.1 \mathrm{mmol})$ was also reacted in acetone ( 20 mL ) with DL-Phe $(\beta-\mathrm{OH})-\mathrm{OH}(0.817 \mathrm{~g}, 4.5 \mathrm{mmol})$ dissolved in $1 \mathrm{~N} \mathrm{NaOH}(10 \mathrm{~mL}, 0.018 \mathrm{~g}, 4.5 \mathrm{mmol})$ for 50 h at room temperature. Boc-Val- $\Delta$ Phe- $\Delta$ Phe-dl-Phe $(\beta$-OH)-OH (6) was obtained after usual workup and was azlactonized using acetic anhydride (20 mL ) and sodium acetate ( $0.345 \mathrm{~g}, 4.2 \mathrm{mmol}$ ) to yield Boc-Val- $\Delta$ Phe$\Delta$ Phe- $\Delta$ Phe-azlactone (7), which showed a single spot on TLC.

To a solution of peptide $7(0.914 \mathrm{~g}, 1.44 \mathrm{mmol})$ in dichloromethane was added $\mathrm{HCl} \cdot \mathrm{Val}-\mathrm{OMe}(0.365 \mathrm{~g}, 2.2 \mathrm{mmol})$ and triethylamine ( 0.3 $\mathrm{mL}, 2.2 \mathrm{mmol}$ ). The reaction mixture was stirred for 80 h . The reaction mixture was then washed with $\mathrm{NaHCO}_{3}$ solution, $5 \%$ citric acid solution, and water and dried over sodium sulfate. The solvent was removed under reduced pressure to give pentapeptide 1, which was recrystallized from methanol and water. Yield $=60 \%$. Mp $=212-$ $214{ }^{\circ} \mathrm{C}, R_{f}\left[\mathrm{CHCl}_{3}-\mathrm{CH}_{3} \mathrm{OH}(9: 1)\right] 0.63, R_{f}\left[\right.$ butanol-acetic acid- $\mathrm{H}_{2} \mathrm{O}$ (4:1:1)] 0.97; the molecular mass of the pentapeptide determined by ES-MS was 766.4 (calculated molecular mass $=765.904$ ); ${ }^{1} \mathrm{H}$ NMR ( $270 \mathrm{MHz}, \mathrm{CDCl}_{3}$ ) $\delta(\mathrm{ppm}): 9.1(1 \mathrm{H}, \mathrm{s}, \mathrm{NH} \Delta \mathrm{Phe} 4) ; 8.79(1 \mathrm{H}, \mathrm{s} \mathrm{NH}$ $\Delta$ Phe3); 7.75 ( $1 \mathrm{H}, \mathrm{s}, \mathrm{NH} \Delta \mathrm{Phe} 2$ ); 7.65 ( $1 \mathrm{H}, \mathrm{d}, \mathrm{NH}$ Val5); $7.55-7.2$ $\left(18 \mathrm{H}, \mathrm{m}\right.$, aromatic $+\mathrm{C}^{\beta} \mathrm{H}$ protons of $\Delta \mathrm{Phe} 2, \Delta \mathrm{Phe} 3$ and $\left.\Delta \mathrm{Phe} 4\right)$; 4.81 ( $1 \mathrm{H}, \mathrm{d}, \mathrm{NH}$ Val1); 4.55 ( $1 \mathrm{H}, \mathrm{m}, \mathrm{C}^{\alpha} \mathrm{H}$ Val5); 4.12 ( $1 \mathrm{H}, \mathrm{m}, \mathrm{C}^{\alpha} \mathrm{H}$ Val1); 2.3 ( $1 \mathrm{H}, \mathrm{m}, \mathrm{C}^{\beta} \mathrm{H}$ Val1); $1.95\left(1 \mathrm{H}, \mathrm{m}, \mathrm{C}^{\beta} \mathrm{H}\right.$ Val5); 1.2 ( $9 \mathrm{H}, \mathrm{s}, 3$ $\left.\times \mathrm{CH}_{3} \mathrm{Boc}\right) ; 1.1\left(6 \mathrm{H}, \mathrm{dd}, \mathrm{C}^{\gamma} \mathrm{H}\right.$ Val1); $0.9\left(6 \mathrm{H}, \mathrm{dd}, \mathrm{C}^{\gamma} \mathrm{H}\right.$ Val1) .

X-ray Diffraction. Single crystals of peptide 1 were grown by controlled evaporation of the peptide $\left(\mathrm{C}_{43} \mathrm{H}_{51} \mathrm{~N}_{5} \mathrm{O}_{8}, M_{\mathrm{w}}=765.9\right)$ in aqueous methanol solution at $4^{\circ} \mathrm{C}$. A colorless crystal mounted on a glass fiber was used for X-ray diffraction experiments. The crystals belong to orthorhombic space group $P 2_{1} 2_{2} 2_{1}, a=11.624(2), b=$ $17.248(2), c=21.532(2) \AA, V=4216(1) \AA^{3}, Z=4, d_{\mathrm{c}}=1.18 \mathrm{~g} \mathrm{~cm}^{-3}$. Three-dimensional X-ray intensity data were collected on an EnrafNonius CAD4 diffractometer with Ni filtered $\mathrm{Cu} \mathrm{K}_{\alpha}$ radiation ( $\lambda=$ $1.5418 \AA$ ) up to a Bragg angle of $65^{\circ}$ using $\omega-2 \theta$ scan method. A total of 4083 unique reflections were collected of which 3213 had $\left|F_{0}\right|$ $>4 \sigma\left|F_{\mathrm{o}}\right|$. No significant variation was observed in the intensities of three standard reflections monitored at regular intervals during data collection implying the electronic and crystal stability. Lorentz and polarization corrections were applied to the data, and no absorption correction was made ( $\mu=6.3 \mathrm{~cm}^{-1}$ ). The structure was solved by direct methods using the computer program SHELXS86 ${ }^{7}$ and refined on $|F|^{2}$ using all 4083 reflections by full-matrix least-squares procedures using the computer program SHELXL93. ${ }^{7}$ All the hydrogen atoms were fixed using stereochemical criteria and used only for structure factor calculations. The conventional $R$-factor R1 based on $|F|$ 's for 3213 reflections with $\left|F_{\mathrm{o}}\right|>4 \sigma\left|F_{\mathrm{o}}\right|$ is $3.64 \%$ and $5.45 \%$ for all 4083 data. The weighted $R$-factor wR2 based on $\left|F_{\mathrm{o}}\right|^{2}$ is $9.79 \%$ for all 4083 data $\left\{w=1 /\left[\sigma^{2}\left|F_{\mathrm{o}}\right|^{2}+(0.0482+P)^{2}+0.7+P\right], P=\left(\max \left(\left|F_{\mathrm{o}}\right|^{2}, 0\right)\right.\right.$ $\left.\left.+2+\left|F_{\mathrm{c}}\right|^{2}\right) / 3\right\}$. The maximum and minimum residual electron density in the final difference fourier map are 0.15 and $-0.16 \mathrm{e}^{-3}$, respectively.

Spectroscopic Studies. ${ }^{1} \mathrm{H}$ NMR spectra were recorded on a Bruker 400 MHz FT NMR at Sophisticated Instruments Facility, Indian Institute of Science. Spectral width of 10 ppm was used for both one- and twodimensional spectra. All chemical shifts are expressed as $\delta(\mathrm{ppm})$ downfield from internal reference tetramethylsilane. Spectra were recorded at concentration of $5 \mathrm{mg} / \mathrm{mL}$. Two-dimensional COSY ${ }^{8 a}$ and ROESY ${ }^{8 b}$ spectra were recorded in $\mathrm{CDCl}_{3}$ at room temperature using standard procedures. Short mixing time ( $200-300 \mathrm{~ms}$ ) was used in the ROESY experiment in order to minimize spin-diffusion effects. Data block sizes were 1024 addresses in $t_{2}$ and 512 equidistant $t_{1}$ values. Circular dichroism (CD) measurements were carried out on a JASCO 500 spectropolarimeter equipped with a data processor 500 N . A 1 mm path length cell was used. The spectra were recorded in three different solvents-chloroform, methanol, and trifluoroethanol. The spectra were normalized for concentration and path length to obtain the mean residue ellipticity after base line correction. The theoretical CD calculations were carried out on the basis of the exciton chirality method. For $\Delta$ Phe chromophore, only the low energy $\pi-\pi^{*}$ transition at 280 nm was considered, and the calculations were carried out as reported earlier. ${ }^{9}$

## Results

Crystal Structure. The bond lengths and bond angles are listed in Tables 1 and 2, respectively. All bond lengths and bond angles are normal except those corresponding to the three $\Delta$ Phe residues. The $\mathrm{C}^{\alpha}=\mathrm{C}^{\beta}$ bond length in the three $\Delta \mathrm{Phe}$ residues are $1.331(4), 1.324(5)$, and $1.326(5) \AA$, respectively, which corresponds to classical $\mathrm{C}=\mathrm{C}$ double bond. The $\mathrm{N}-\mathrm{C}^{\alpha}$ [1.418(4), 1.419(3), and 1.421(4) $\AA$ ] and $\mathrm{C}^{\alpha}-\mathrm{C}^{\prime}$ [1.490(5), 1.500(5), and 1.501(5) Å] bond distances in $\Delta$ Phe residues are slightly shorter than the corresponding bonds in saturated residues ( 1.45 and $1.53 \AA$, respectively ${ }^{10}$ ), as seen in other $\Delta$ Phe peptides. ${ }^{5 g-t}$ This shortening is probably due to the extended conjugation of the $\Delta$ Phe ring electrons and the remaining part of the residue.

[^1]Table 1. Bond Distances (in $\AA$ Units) Involving the Non-Hydrogen Atoms of the Pentapeptide Boc-L-Val- $\Delta$ Phe- $\Delta$ Phe- $\Delta$ Phe-L-Val-OMe

| atom1-atom2 | distance ( A ) | atom1-atom2 | distance ( A ) | atom1-atom2 | distance ( A ) |
| :---: | :---: | :---: | :---: | :---: | :---: |
| C1-C4 | 1.511(6) | C2-C4 | 1.504(7) | C3-C4 | 1.513(8) |
| C4-O1 | 1.481(5) | O1-C5 | 1.344(4) | C5-O2 | 1.217(4) |
| C5-N1 | 1.336 (3) | N1-C1A | 1.451(4) | C1A-C1 ${ }^{\prime}$ | 1.517(4) |
| C1A-C1B | 1.540(4) | $\mathrm{C1}^{\prime}-\mathrm{O} 1^{\prime}$ | 1.223(4) | $\mathrm{C} 1^{\prime}-\mathrm{N} 2$ | 1.344 (3) |
| C1B-C1G1 | $1.508(6)$ | C1B-C1G2 | $1.519(6)$ | N2-C2A | 1.418(4) |
| C2A-C2 ${ }^{\prime}$ | 1.490 (5) | C2A-C2B | 1.331(4) | $\mathrm{C} 2^{\prime}-\mathrm{O} 2^{\prime}$ | 1.229(4) |
| $\mathrm{C} 2{ }^{\prime}-\mathrm{N} 3$ | $1.360(4)$ | $\mathrm{C} 2 \mathrm{~B}-\mathrm{C} 2 \mathrm{G}$ | 1.467 (6) | C2G-C2D1 | $1.386(6)$ |
| C2G-C2D2 | 1.370 (5) | C2D1-C2E1 | $1.389(6)$ | C2D2-C2E2 | 1.377(6) |
| C2E1-C2Z | $1.360(7)$ | C2E2-C2Z | $1.362(6)$ | N3-C3A | $1.419(3)$ |
| C3A-C3' | $1.500(5)$ | C3A-C3B | $1.324(5)$ | C3'-O3' | 1.216 (3) |
| $\mathrm{C} 3^{\prime}-\mathrm{N} 4$ | 1.360 (3) | C3B-C3G | $1.480(5)$ | C3G-C3D1 | 1.371(7) |
| C3G-C3D2 | $1.385(5)$ | C3D1-C3E1 | $1.380(9)$ | C3D2-C3E2 | $1.400(9)$ |
| C3E1-C3Z | $1.349(10)$ | C3E2-C3Z | 1.343 (13) | N4-C4A | $1.421(4)$ |
| C4A-C4' | $1.500(5)$ | C4A-C4B | $1.326(5)$ | C4'-O4' | 1.226(4) |
| $\mathrm{C} 4{ }^{-} \mathrm{N} 5$ | $1.342(4)$ | C4B-C4G | $1.459(5)$ | C4G-C4D1 | $1.391(5)$ |
| C4G-C4D2 | $1.392(5)$ | C4D1-C4E1 | $1.383(5)$ | C4D2-C4E2 | $1.365(6)$ |
| C4E1-C4Z | 1.376 (6) | C4E2-C4Z | 1.361(7) | N5-C5A | 1.445 (4) |
| C5A-C5' | 1.502(6) | C5A-C5B | 1.534(6) | C5'-O5' | 1.173(6) |
| C5'-O3 | $1.299(5)$ | C5B-C5G1 | 1.508(7) | C5B-C5G2 | 1.521(7) |
| O3-C6 | 1.457(10) |  |  |  |  |

Table 2. Bond Angles (in deg) Involving the Non-Hydrogen Atoms of the Pentapeptide Boc-L-Val- $\Delta$ Phe- $\Delta$ Phe- $\Delta$ Phe-L-Val-OMe

| atom1-atom2-atom3 | angle (deg) | atom1-atom2-atom3 | angle (deg) | atom1-atom2-atom3 | angle (deg) |
| :---: | :---: | :---: | :---: | :---: | :---: |
| C2-C4-C3 | 111.3(4) | C1-C4-C3 | 111.8(4) | C1-C4-C2 | 112.6(4) |
| C3-C4-O1 | 101.6(3) | C2-C4-O1 | 110.2(3) | $\mathrm{C} 1-\mathrm{C} 4-\mathrm{O} 1$ | 108.8(3) |
| C4-O1-C5 | 121.7(3) | $\mathrm{O} 1-\mathrm{C} 5-\mathrm{N} 1$ | 109.8(3) | O1-C5-O2 | 125.5(2) |
| O2-C5-N1 | 124.7(3) | C5-N1-C1A | 120.1(3) | $\mathrm{N} 1-\mathrm{C} 1 \mathrm{~A}-\mathrm{C} 1 \mathrm{~B}$ | 111.6(3) |
| $\mathrm{N} 1-\mathrm{C} 1 \mathrm{~A}-\mathrm{C} 1^{\prime}$ | 110.7(2) | C1'-C1A-C1B | 110.3(3) | $\mathrm{C} 1 \mathrm{~A}-\mathrm{C} 1^{\prime}-\mathrm{N} 2$ | 114.2(3) |
| $\mathrm{C} 1 \mathrm{~A}-\mathrm{Cl}^{\prime}-\mathrm{Ol}^{\prime}$ | 123.4(3) | $\mathrm{O1}^{\prime}-\mathrm{Cl}^{\prime}-\mathrm{N} 2$ | 122.4(3) | C1A-C1B-C1G2 | 110.7(3) |
| C1A-C1B-C1G1 | 113.4(2) | C1G1-C1B-C1G2 | 112.2(3) | $\mathrm{Cl}^{\prime}-\mathrm{N} 2-\mathrm{C} 2 \mathrm{~A}$ | 123.9(2) |
| N2-C2A-C2B | 122.5(3) | $\mathrm{N} 2-\mathrm{C} 2 \mathrm{~A}-\mathrm{C} 2^{\prime}$ | 116.9(2) | C2'-C2A-C2B | 120.3(3) |
| $\mathrm{C} 2 \mathrm{~A}-\mathrm{C} 2^{\prime}-\mathrm{N} 3$ | 116.3(3) | $\mathrm{C} 2 \mathrm{~A}-\mathrm{C} 2^{\prime}-\mathrm{O} 2^{\prime}$ | 122.3(3) | $\mathrm{O} 2^{\prime}-\mathrm{C} 2^{\prime}-\mathrm{N} 3$ | 121.4(3) |
| C2A-C2B-C2G | 128.8(3) | C2B-C2G-C2D2 | 119.3(4) | C2B-C2G-C2D1 | 123.6(3) |
| C2D1-C2G-C2D2 | 117.0(4) | C2G-C2D1-C2E1 | 121.3(4) | C2G-C2D2-C2E2 | 121.7(4) |
| C2D1-C2E1-C2Z | 120.0(4) | C2D2-C2E2-C2Z | 120.5(4) | C2E1-C2Z-C2E2 | 119.4(4) |
| $\mathrm{C} 2{ }^{\prime}-\mathrm{N} 3-\mathrm{C} 3 \mathrm{~A}$ | 122.0(2) | N3-C3A-C3B | 122.4(3) | N3-C3A-C3' | 118.0(2) |
| C3'-C3A-C3B | 119.5(3) | C3A-C3'-N4 | 115.5(2) | C3A-C3'-O3' | 121.8(3) |
| O3'-C3'-N4 | 122.7(3) | C3A-C3B-C3G | 126.3(4) | C3B-C3G-C3D2 | 121.1(4) |
| C3B-C3G-C3D1 | 120.9(4) | C3D1-C3G-C3D2 | 118.0(4) | C3G-C3D1C3E1 | 121.0(5) |
| C3G-C3D2-C3E2 | 119.7(5) | C3D1-C3E1-C3Z | 120.5(7) | C3D2-C3E2-C3Z | 120.6(5) |
| C3E1-C3Z-C3E2 | 120.1(7) | C3'-N4-C4A | 121.0(2) | N4-C4A-C4B | 123.5(3) |
| $\mathrm{N} 4-\mathrm{C} 4 \mathrm{~A}-\mathrm{C} 4^{\prime}$ | 116.8(3) | C4'-C4A-C4B | 119.6(3) | $\mathrm{C} 4 \mathrm{~A}-\mathrm{C} 4^{\prime}-\mathrm{N} 5$ | 116.4(3) |
| C4A-C4'-O4' | 121.7(3) | $\mathrm{O} 4^{\prime}-\mathrm{C} 4^{\prime}-\mathrm{N} 5$ | 121.8(3) | $\mathrm{C} 4 \mathrm{~A}-\mathrm{C} 4 \mathrm{~B}-\mathrm{C} 4 \mathrm{G}$ | 130.9(3) |
| C4B-C4G-C4D2 | 118.3(4) | C4B-C4G-C4D1 | 124.2(3) | C4D1-C4G-C4D2 | 117.4(3) |
| C4G-C4D1-C4E1 | 120.6(3) | C4G-C4D2-C4E2 | 121.8(4) | C4D1-C4E1-C4Z | 119.9(4) |
| C4D2-C4E2-C4Z | 119.8(4) | C4E1-C4Z-C4E2 | 120.4(4) | C4'-N5-C5A | 121.8(3) |
| N5-C5A-C5B | 113.7(3) | N5-C5A-C5' | 111.6(3) | C5'-C5A-C5B | $110.2(3)$ |
| C5A-C5'-O3 | 115.3(4) | C5A-C5'-O5' | 122.1(4) | O5'-C5'-O3 | 122.6(4) |
| C5A-C5B-C5G2 | 112.9(4) | C5A-C5B-C5G1 | 111.0(4) | C5G1-C5B-C5G2 | 110.9(4) |
| C5-O3-C6 | 115.9(5) |  |  |  |  |

The shortening of the bond length $\mathrm{C}^{\alpha}=\mathrm{C}^{\beta}$ because of the double bond and increased planarity of the dehydro residue as a whole because of $\mathrm{sp}^{2}$ hybridized $\alpha$ and $\beta$ carbon atoms leads to certain unfavorable steric contacts between the side-chain and main-chain atoms of the $\Delta$ Phe residue. These steric contacts are partly released by rearrangement of bond angles at $\alpha$ and $\beta$ carbon atoms. For example, the bond angle $\mathrm{N}-\mathrm{C}^{\alpha-}$ $\mathrm{C}^{\prime}$ [116.9(2), 118.0(2), and $116.8(3)^{\circ}$ in $\Delta \mathrm{Phe}^{2}, \Delta \mathrm{Phe}^{3}$, and $\Delta \mathrm{Phe}^{4}$, respectively] is reduced from the standard trigonal value of $120^{\circ}$, while the angles $\mathrm{N}-\mathrm{C}^{\alpha}=\mathrm{C}^{\beta}$ [122.5(3), 122.4(3), and 123.5(3) ${ }^{\circ}$ ] and $\mathrm{C}^{\alpha}=\mathrm{C}^{\beta-} \mathrm{C}^{\gamma}$ [128.8(3), 126.3(4) and 130.9(3) ${ }^{\circ}$ ] are increased.

The torsion angles that characterize the Boc group, $\omega^{0}$ and $\theta^{1}$, assume values of $-172.3(2)^{\circ}$ and $-179.0(3)^{\circ}$, respectively, which corresponds to a trans-trans conformation. ${ }^{11}$ This particular conformation of the Boc group makes it possible for O (Boc) atom to participate in the first $4 \rightarrow 1$ intramolecular hydrogen bond. The values of $\omega^{0}$ and $\theta^{1}$ represent a generally
preferred ${ }^{11}$ planar urethane moiety [between C 1 (Boc) and $\mathrm{C} 1^{\alpha}$ ]. The dihedral angle $\mathrm{C} 1-\mathrm{O} 1-\mathrm{C} 5-\mathrm{O} 2\left(\theta^{1^{\prime}}\right)$ has a value of $0.4-$ $(4)^{\circ}$, indicating that $\mathrm{C} 5-\mathrm{O} 2$ bond is syn planar with $\mathrm{C} 1-\mathrm{O} 1$ bond, as seen for urethane in general. ${ }^{12}$ The three methyl carbon atoms of the Boc group assume energetically favorable staggered positions with respect to the $\mathrm{O} 1-\mathrm{C} 5$ bond $\left[\theta^{2}{ }_{1}=62.0(4), \theta^{2}{ }_{2}\right.$ $=180.0(3)$, and $\left.\theta^{2}{ }_{3}=-62.0(4)^{\circ}\right]$.

The peptide molecule is characterized by a left-handed $3_{10^{-}}$ helical conformation (Figures 1, 5, and 6) composed of three consecutive, overlapping $\beta$-bends stabilized by appropriate 4 $\rightarrow 1$ intramolecular $\mathrm{N}-\mathrm{H} \cdots \mathrm{O}$ hydrogen bond (Table 3). The first $\beta$-bend is a type II $\beta$-bend ( $-\mathrm{L}-\mathrm{Val}^{1}-\Delta \mathrm{Phe}^{2}$-) which is nonhelical, while the other two are type $\mathrm{III}^{\prime}\left(\Delta \mathrm{Phe}^{2}-\Delta \mathrm{Phe}^{3}-\right)$ and type $\mathrm{I}^{\prime} \beta$-bends( $\Delta \mathrm{Phe}^{3}-\Delta \mathrm{Phe}^{4}$-). The average main chain
(11) Benedetti, E.; Pedone, C.; Toniolo,C.; Nemathy, G.; Pottle, M. S.; Scheraga, H. A. Int. J. Peptide Protein Res. 1980, 16, 156.
(12) (a) Bender, M. L. Chem. Rev. 1960, 60, 53. (b) Dunitz, J. D.; Strickler, P. In Structural Chemistry and Molecular Biology, Rich, A., Davidson, N., Eds.; Freeman: San Fransisco, 1968, pp 595.

Table 3. Main Chain Torsion Angles in the Solid State Conformation of the Pentapeptide Boc-L-Val- $\Delta$ Phe- $\Delta$ Phe- $\Delta$ Phe-L-Val-OMe

| residue | i | $\phi_{\mathrm{i}}$ | $\psi_{\mathrm{i}}$ | $\omega_{\mathrm{i}}$ | $\chi_{\mathrm{i}}^{1,1}$ | $\chi_{\mathrm{i}}^{1,2}$ | $\chi_{\mathrm{i}^{2}}{ }^{2,1}$ |
| :--- | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Boc | 0 |  |  | $-172.3(2)$ |  |  |  |
| Val | 1 | $-56.0(3)$ | $131.2(3)$ | $179.8(2)$ | $52.3(4)$ | $-74.8(4)$ | $28.3(6)$ |
| $\Delta$ Phe | 2 | $56.0(4)$ | $18.4(4)$ | $-168.3(3)$ | $5.2(6)$ | $-150.3(4)$ |  |
| $\Delta$ Phe | 3 | $58.1(4)$ | $13.0(4)$ | $-171.3(3)$ | $9.2(4)$ | $-125.9(5)$ |  |
| $\Delta$ Phe | 4 | $78.2(4)$ | $4.5(4)$ | $178.0(3)$ | $1.6(6)$ | $-148.5(4)$ |  |
| Val | 5 | $-122.5(3)$ |  |  | $-60.5(5)$ | $64.3(6)$ | $-32.7(7)$ |



Figure 1. Molecular structure of Boc-L-Val- $\Delta$ Phe- $\Delta$ Phe- $\Delta$ Phe-L-ValOMe showing left-handed helical conformation. Dotted lines indicate the intramolecular $4 \rightarrow 1$ hydrogen bonds.
dihedral angles for the three $\Delta$ Phe residues are $\langle\phi\rangle=64.1^{\circ}$ and $\langle\psi\rangle=12.0^{\circ}$; a slight deviation in $\psi$ from the observed $3_{10^{-}}$ helical value in peptides ${ }^{13 \mathrm{a}, \mathrm{b}}\left(30^{\circ}\right)$ and proteins ${ }^{13 \mathrm{c}}\left(18^{\circ}\right)$. As noted by others ${ }^{14}$ the presence of a type $\mathrm{I}^{\prime} \beta$-bend in a $3_{10}$-helix does not disturb the helicity.

The two Val residues ( $\mathrm{Val}^{1}$ and $\mathrm{Val}^{5}$ ) in the pentapeptide assume similar side-chain conformations (Table 3) and so do the side-chain torsion angle $\chi^{1}$ of the three $\Delta$ Phe residues. However, the signs of the side-chain torsion angles $\chi^{2,1}$ and $\chi^{2,2}$ for $\Delta \mathrm{Phe}^{4}$ residue are opposite to those for $\Delta \mathrm{Phe}^{2}$ and $\Delta \mathrm{Phe}^{3}$ residues. Model building suggests that this is probably to release unfavorable steric interactions between the bulky side chains of $\Delta$ Phe residues which arise because of increase in $\phi$ torsion angle in $\Delta \mathrm{Phe}^{4}$ approximately by $20^{\circ}$ (Table 3 ). In solid state each peptide molecule interacts with four other molecules through one hydrogen bond each (Figure 2). N1 donates a hydrogen bond to O4ó of a symmetry related molecule, while N 2 donates a hydrogen bond to O5ó of another symmetry related molecule (Table 4). No helical rods are observed in the solid state; a frequent feature observed in the crystal structure of helical peptide molecules. ${ }^{5 n, 6 a}$

Solution Conformation. Well-resolved ${ }^{1} \mathrm{H}$ NMR spectra were obtained for pentapeptide $\mathbf{1}$ in $\mathrm{CDCl}_{3}$. Assignments were made by standard two-dimensional NMR techniques. ${ }^{8}$ The relevant NMR parameters for the NH group resonances in the pentapeptide are given in Table 5. Solvent titration experiments in $\mathrm{CDCl}_{3}-\left(\mathrm{CD}_{3}\right)_{2} \mathrm{SO}$ mixtures establish that only two NH group resonances, assigned to Vall and $\Delta \mathrm{Phe} 2$, move appreciably

[^2]

Figure 2. Crystal packing of Boc-L-Val- $\Delta$ Phe- $\Delta$ Phe- $\Delta$ Phe-L-Val-OMe. View down the crystallographic $b$ axis.
downfield on addition of the strongly hydrogen-bonding solvent, $\left(\mathrm{CD}_{3}\right)_{2} \mathrm{SO}$, to solution in the apolar solvent, $\mathrm{CDCl}_{3}$. Also, both Val1 and $\Delta \mathrm{Phe} 2 \mathrm{NH}$ resonances exhibit high temperature coefficient ( $\mathrm{d} \delta / \mathrm{d} t>0.004 \mathrm{ppm} / \mathrm{K}$ ) in $\left(\mathrm{CD}_{3}\right)_{2} \mathrm{SO}$ (Table 5), indicating that these NHs are not intramolecularly hydrogen bonded as they are exposed to the solvent for intermolecular hydrogen bonding. ${ }^{15}$ On the other hand the remaining NH resonances ( $\Delta \mathrm{Phe} 3, \Delta \mathrm{Phe} 4$, and Val5) show characteristics of solvent-shielded (intramolecular hydrogen bond) NH groups. ${ }^{15 \mathrm{a}}$ These observation together with the known stereochemical preferences of $\Delta$ Phe residues to favor $\beta$-turn conformations ${ }^{1}$ stabilized by intramolecular $4 \rightarrow 1$ hydrogen bond suggest that consecutive $\beta$-turn conformations are populated in solvents like chloroform. Both type III-III-III ( $\phi_{1}=\phi_{2}=\phi_{3}=\phi_{4} \sim-60^{\circ}$ and $\psi_{1}=\psi_{2}=\psi_{3}=\psi_{4} \sim-30^{\circ}$ ) and type II-III'-III' $\left(\phi_{1} \sim\right.$ $-60^{\circ}, \psi_{1} \sim 120, \phi_{2}=\phi_{3}=\phi_{4}=60^{\circ}$, and $\psi_{1}=\psi_{2}=\psi_{3} \sim$ $30^{\circ}$ ) structures ${ }^{4}$ are compatible with the pentapeptide sequence. In the former arrangement, L-Val would have torsion angle $\phi$ $\sim-60^{\circ}, \psi \sim-30^{\circ}$, and the three $\Delta$ Phe residues at positions 2,3 , and 4 would lie in the right-handed helical region of the $\phi, \psi$ map. In the latter arrangement, L-Val would have $\phi_{1} \sim 60^{\circ}$, $\psi_{1} \sim 120^{\circ}$, and the $\Delta \mathrm{Phe} 2, \Delta \mathrm{Phe} 3$, and $\Delta \mathrm{Phe} 4$ would lie in the left-handed region. ${ }^{16}$ A distinction between type II and type III $\beta$-turn conformation may be readily made by NMR method using NOEs ${ }^{16}$ between $\mathrm{C}_{\mathrm{i}}{ }^{\alpha} \mathrm{H}$ and $\mathrm{N}_{i+1} \mathrm{H}$ protons in the ROESY ${ }^{17}$ spectrum (Figure 3). A strong cross peak is observed between $\mathrm{C}^{\alpha} \mathrm{H} \operatorname{Val}(1)$ and $\mathrm{NH} \Delta \mathrm{Phe}(2)$ suggesting close approach ( $<3$ $\AA$ ) of the Val $\mathrm{C}^{\alpha} \mathrm{H}$ and $\Delta$ Phe NH groups, ${ }^{18}$ supporting a type II $\beta$-turn conformation for the $\operatorname{Val}(1)-\Delta \mathrm{Phe}(2)$ segment which in fact is the case in crystal structure also. Another evidence in

[^3]

Figure 3. 400 MHz ROESY spectrum of Boc-L-Val- $\Delta$ Phe- $\Delta$ Phe- $\Delta$ Phe-L-Val-OMe in $\mathrm{CDCl}_{3}$ at room temperature. The cross peaks are represented by the numbers.

Table 4. Intermolecular and Intramolecular Hydrogen Bonds Observed in the Crystal Structure of the Pentapeptide Boc-L-Val- $\Delta$ Phe- $\Delta$ Phe- $\Delta$ Phe-L-Val-OMe

| donor D | acceptor A | distance $\mathrm{D}-\mathrm{A}(\AA)$ | distance $\mathrm{H}-\mathrm{A}(\AA)$ | angle $\mathrm{D}-\mathrm{H}-\mathrm{A}(\mathrm{deg})$ | symmetry |
| :---: | :--- | :---: | :---: | :---: | :---: |
| $\mathrm{N}_{1}$ | $\mathrm{O}_{4}^{\prime}$ | $2.880(3)$ | $2.115(3)$ | $148.0(2)$ | $-x, y+0.5,-z+1.5$ |
| $\mathrm{~N}_{2}$ | $\mathrm{O}_{5}^{\prime}$ | $2.737(4)$ | $1.929(4)$ | $155.6(6)$ | $-x+1, y+0.5,-z+1.5$ |
| $\mathrm{~N}_{3}$ | $\mathrm{O}_{2}(\mathrm{Boc})$ | $2.913(3)$ | $2.165(3)$ | $145.1(3)$ | $x, y, z$ |
| $\mathrm{~N}_{4}$ | $\mathrm{O}_{1}^{\prime}$ | $2.890(3)$ | $2.041(3)$ | $168.6(3)$ | $x, y, z$ |
| $\mathrm{~N}_{5}$ | $\mathrm{O}_{2}^{\prime}$ | $2.964(3)$ | $2.141(3)$ | $160.3(2)$ | $x, y, z$ |

Table 5. NMR Parameters for NH Protons in the Pentapeptide Boc-L-Val- $\Delta$ Phe- $\Delta$ Phe- $\Delta$ Phe-L-Val-OMe

| residues | $\mathrm{CDCl}_{3}$ <br> $(\mathrm{ppm})$ | $\left(\mathrm{CD}_{3}\right)_{2} \mathrm{SO}$ <br> $(\mathrm{ppm})$ | $\Delta$ <br> $(\mathrm{ppm})$ | $\mathrm{d} \delta / \mathrm{d}_{2}\left[\left(\mathrm{CD}_{3}\right)_{2} \mathrm{SO}\right]$ <br> $\left(10^{-3} \mathrm{ppm} / \mathrm{K}\right)$ | $3_{J_{\mathrm{NH}}}$ <br> value $(\mathrm{in} \mathrm{Hz})$ |
| :--- | :---: | :---: | :---: | :---: | :---: |
| $\operatorname{Val(1)}$ | 4.80 | 7.25 | 2.45 | 10.00 | 4.00 |
| $\Delta \operatorname{Phe}(2)$ | 7.71 | 10.30 | 2.59 | 4.57 |  |
| $\Delta \operatorname{Phe}(3)$ | 8.79 | 10.00 | 1.21 | 2.67 |  |
| $\Delta \operatorname{Phe}(4)$ | 9.17 | 9.45 | 0.28 | 3.50 |  |
| $\operatorname{Val(5)}$ | 7.65 | 7.80 | 0.15 | 1.00 | 8.75 |

support of the type II $\beta$-turn is the absence of NOE between NH Val(1) and NH $\Delta$ Phe ( 2 ), since such $\mathrm{N}_{i+1} \mathrm{H} \leftrightarrow \mathrm{N}_{i+2} \mathrm{H}$ NOEs are expected only in a type I $\beta$-turn, where an interproton distance of $2.6 \AA$ is estimated ${ }^{18 \mathrm{~b}}$. The corresponding distance in a type II $\beta$-turn is $4.5 \AA$, and therefore no NOE was observed between NH Val(1) and NH $\Delta \mathrm{Ph}(2)$ as expected.

Apart from this, NOEs between $\Delta$ Phe (3) NH $\leftrightarrow \Delta$ Phe(4) NH $\leftrightarrow \operatorname{Val}(5) \mathrm{NH}$ are also observed in the ROESY spectrum (Figure 3). The observation of successive $\mathrm{N}_{i+1} \leftrightarrow \mathrm{~N}_{i+2}$ NOE connectivities is diagnostic of a $3_{10}$ or $\alpha$-helical conformation over the three residues. ${ }^{18 \mathrm{~b}}$ To differentiate between a $3_{10}$ and $\alpha$-helical conformation medium range NOEs of the type $\mathrm{d}_{\alpha \mathrm{N}}$ $(i, i+2$ or $i, i+3)$ have been used. ${ }^{19}$ However, since successive $\Delta$ Phe residues, which lack $\mathrm{C}^{\alpha} \mathrm{H}$ proton, are present in the pentapeptide, medium range $d_{\alpha N}$ NOEs were not observed, and

[^4]therefore unambiguous assignment of the type of helical conformation could not be made. But in the light of other NOE data ( $d_{\mathrm{NN}}$ and $d_{\alpha \mathrm{N}}$ cross peaks) and temperature and solvent dependence studies, it is clear that the pentapeptide adopts consecutive $\beta$-turn (helical) conformation in solvent like $\mathrm{CDCl}_{3}$. The observed ${ }^{3} J_{\mathrm{NH} \alpha}$ values in $\mathrm{CDCl}_{3}$ were $4.0 \mathrm{~Hz}[\mathrm{Val}(1)]$ and $8.75 \mathrm{~Hz}[\mathrm{Val}(5)]$, and the corresponding $\phi$ angles obtained with Karplus like equation ${ }^{8,20}$ were $\phi[\operatorname{Val}(1)]=105^{\circ}, 15^{\circ},-174^{\circ}$, $-66^{\circ}$ and $\phi[\operatorname{Val}(5)]=-142^{\circ},-98^{\circ}$. The torsional angles $-66^{\circ}$ $[\mathrm{Val}(1)]$ and $-142^{\circ}[\mathrm{Val}(5)]$ are in agreement with the conformation proposed for the pentapeptide.

Circular dichroism studies were carried out in three different solvents-chloroform, methanol, and trifluoroethanol-to probe the screw sense of the peptide chain conformation. In all the solvents, the peptide displays a couplet ( +- ) of intense bands with opposite signs at 285 and 260 nm and a crossover at 275 nm (Figure 4). This kind of splitting pattern originates from the rigid disposition of the $\Delta$ Phe residues involved in a system of consecutive $\beta$-turns, such as a $3_{10}$-helix. ${ }^{51,9,21}$ The sign of the couplet $(+-)$ in case of $\mathbf{1}$ is opposite to that observed for dehydro peptides having right-handed screw sense. ${ }^{51}$ The most likely explanation for the different signs is the presence of a preferred conformation having opposite chirality, i.e., left-handed $33_{10}$-helix. The theoretical CD calculations were also carried
(20) Karplus, M. J. J. Chem. Phys. 1959, 30, 11.
(21) Pieroni, O.; Fissi, A,; Jain, R. M.; Chauhan, V. S. Biopolymers 1996, 38, 97.



Figure 4. Theoretical (top) and experimental (bottom) CD spectra of Boc-L-Val- $\Delta$ Phe- $\Delta$ Phe- $\Delta$ Phe-L-Val-OMe.
out with several $3_{10}$-type helix main-chain torsion angles including the angles from the crystallographic data. The calculations are based on the spatial array of dehydro Phe residues, of 280 nm transition moment by MO calculation, the planarity of $\mathrm{NC}^{\alpha}-\mathrm{C}^{\beta}-\mathrm{C}=\mathrm{O}$ in dehydro Phe residue was assumed, and thus $\chi^{1,1}$ of dehydro Phe was fixed to $0^{\circ}$. The theoretical CD spectra obtained for the pentapeptide is similar to the experimental CD spectra giving a positive exciton couplet (positive peak at longer wavelength) as shown in Figure 4. This supports that the pentapeptide forms a left-handed helix.

## Discussion

Structure elucidation of pentapeptide $\mathbf{1}$ is the first report of a dehydropeptide containing three consecutive $\Delta$ Phe residues, which may reflect on the conformational preference of poly ( $\Delta \mathrm{Phe}$ ) system; this was the main purpose of the present study. The peptide molecule exhibits preference for left-handed $3_{10^{-}}$ helical conformation, in spite of the presence of two L-Val residues (Figure 1). The terminal L-Val residues ( $\mathrm{L}-\mathrm{Val}^{1}$ and $\mathrm{L}-\mathrm{Val}{ }^{5}$ ) are not strictly helical as indicated by their main chain torsion angles (Table 4). As mentioned earlier the segment centered around $-\mathrm{L}-\mathrm{Val}^{1}-\Delta \mathrm{Phe}^{2}$ - exhibits a type II $\beta$-bend; a nonhelical turn conformation and $\mathrm{L}-\mathrm{Val}{ }^{1}$ residue adopts a
semiextended conformation typical of $i+1$ position of type II $\beta$-turn. In Aib rich peptides it is observed that when the N -terminal -X-Aib sequence is of type II $\beta$-bend conformation, the adjacent segment of the peptide chain is forced to adopt the left-handed $3_{10}$-helical conformation even if the peptide sequence contains some L residues. ${ }^{22 a m}$ Also from model building it can be seen that if a type II $\beta$-bend is followed by a helix, this helix would tend to be left-handed, because of steric reasons. The deviation of terminal L-Val residues from helical conformation is not surprising considering the fact that L residues are not usually part of left-handed helices and instead accommodated in right-handed helices. In a peptide containing two consecutive $\Delta$ Phe residues (Boc-L-Ala- $\Delta$ Phe- $\Delta$ Phe-NHMe) ${ }^{5 j}$ both lefthanded and right-handed helical structures were observed. Interestingly, although the L-Ala residue was part of the helix in both cases, it was found to be more distorted in the lefthanded conformer.

Left-handed helical conformation is also observed in a few peptides containing Aib residues. ${ }^{22}$ Fully blocked $(\mathrm{Aib})_{n}(n=$ $3-8,10$ ) homopeptides crystallize in centrosymmetric space groups exhibiting both left, and right-handed $3_{10}$-helical conformation. ${ }^{22 e-1}$ Remarkably, left-handed $3_{10}$-helices are observed in Aib rich peptides viz., Boc-Pro-Aib-Ala-Aib-Ala$\mathrm{OH}, \mathrm{Z}(\mathrm{Cl})$-Pro-Aib-Ala-Aib-Ala-OMe and Ac-(Aib) $2_{2}$-S-Iva(Aib) $)_{2}-\mathrm{OMe},{ }^{22 \mathrm{a}-\mathrm{d}}$ despite the presence of residues of L chirality. In none of the former peptides is L-Pro a part of the helix. Moreover both peptides start with a type II $\beta$-bend at the N -terminus. Surprisingly $\mathrm{Ala}^{3}$ and S-Iva residues in these peptides thought to have L chirality adopt left-handed helical backbone torsion angles. However in the present peptide the terminal L-Val residues do not adopt left-handed helical conformation.

Results of NMR experiments suggest that the pentapeptide tends to maintain $3_{10}$-helical conformation in chloroform. However, the handedness of the helical structure cannot be ascertained by NMR experiments. For this theoretical and experimental CD calculations were carried out. ${ }^{9}$ In fact, CD has been used as a method of choice to monitor the interconversion of a right-handed helix into a left-handed helix in a model dehydrophenylalanine containing peptide, as a function of change in solvent and temperature. ${ }^{23}$ In $\Delta$ Phe containing peptides which adopt right-handed $3_{10}$-helical structures, very similar CD pattern have been observed; ${ }^{9,21}$ the CD spectrum in most cases displays a couplet of intense bands with opposite signs $(-+)$ at $\sim 300 \mathrm{~nm}$ and $\sim 270 \mathrm{~nm}$ and a crossover at $\sim 275-285 \mathrm{~nm}$. This CD pattern is a typical exciton splitting
(22) (a) Bosch, R.; Jung, G.; Schmitt, H.; Sheldrick, G. M.; Winter, W. Angew. Chem. 1984, 96, 440. (b) Bosch, R.; Jung, G.; Schmitt, H.; Winter, W. Acta Crystallogr. 1985, C41, 1821. (c) Cameron, T. S.; Hanson, A. W.; Taylor, A. Cryst. Struct. Commun. 1982, 11, 321. (d) Valle, G.; Crisma, M.; Toniolo, C.; Beisswenger, R.; Rieker, A.; Jung, G. J. Am. Chem. Soc. 1989, 111, 6828. (e) Bavoso, A.; Benedetti, E.; Di Blasio, B.; Pavone, V.; Pedone, C.; Toniolo, C.; Bonora, G. M. Proc. Natl. Acad. Sci. U.S.A. 1986, 83, 1988. (f) Shamala, N.; Nagaraj, R.; Balaram, P. J. Chem. Soc., Chem. Commun. 1978, 996. (g) Rao, Ch.P.; Shamala, N.; Nagaraj, R.; Rao, C. N. R.; Balaram, P. Biochem. Biophys. Res. Commun. 1981, 103, 898. (h) Benedetti, E.; Bavoso, A.; Di Blasio, B.; Pavone, V.; Pedone, C.; Crisma, M.; Bonora, G. M.; Toniolo, C. J. Am. Chem. Soc. 1982, 104, 2437. (i) Di Blasio, B.; Santini, A.; Pavone, V.; Pedone, C.; Benedetti, E.; Moretto, V.; Crisma, M.; Toniolo, C. Struct. Chem. 1991, 2, 523. (j) Pavone, V.; Di Blasio, B.; Pedone, C.; Santini, A.; Benedetti, E.; Formaggio, F.; Crisma, M.; Toniolo, C. Gazz. Chim. Ital. 1991, 121, 21. (k) Pavone, V.; Di Blasio, B.; Santini, A.; Benedetti, E.; Pedone, C.; Toniolo, C.; Crisma, M. J. Mol. Biol. 1990, 214, 633. (1) Toniolo, C.; Crisma, M.; Bonora, G. M.; Benedetti, E.; Di Blasio, B.; Pavone, V.; Pedone, C.; Santini, A. Biopolymers 1991, 31, 129. (m) Prasad, B. V. V; Balaram, P. CRC Crit. Rev. Biochem. 1984, 16, 307.
(23) (a) Pieroni, O.; Fissi, A.; Pratessi, C.; Temmussi, P. A.; Ciardelli, F. J. Am. Chem. Soc. 1991, 113, 6338. (b) Hummel, R.; Toniolo, C.; Jung, G. Angew. Chem. 1987, 26, 1150.


Figure 5. Pentapeptide molecule showing helical sense with side chains.
due to dipole-dipole interaction between charge-transfer electronic transitions of the dehydro chromophores and is a strong indication that the two $\Delta$ Phe residues are placed in mutual fixed disposition within the molecule. This arrangement is possible when at least two dehydro residues are involved in a system of consecutive $\beta$-turns, i.e., a $3_{10}$-helix. ${ }^{9}$ The fact that the sign of the couplet $(+-)$ in case of the present pentapeptide is opposite in both calculated CD spectrum and experimental CD spectra provides the evidence for the existence of large ensemble of left-handed $3_{10}$-helical conformations in solution.

## Conclusion

Given the conformation restricting ability of dehydroamino acids in peptides, the structure determination of polydehydro amino acids is of obvious interest. The present study highlights the conformational consequence of consecutive $\Delta$ Phe residues in peptides. Both crystal studies and solution studies suggest that pentapeptide exclusively adopts a left-handed helical conformation, despite the presence of two L-amino acid residues. Helical structures for poly $(\Delta \mathrm{Ala})^{24}$ have been predicted, which however have yet to be confirmed experimentally. Although no studies are performed on the poly ( $\Delta \mathrm{Phe}$ ) system, the present study suggests that a left-handed helical conformation may be more stable in a peptide containing ( $\Delta \mathrm{Phe})_{n}$ motif. It is however not clear as to why a left-handed helix is preferred despite the presence of two L-amino acids in the sequence. It will therefore be of considerable interest to carry out conformational studies on peptides containing three or more consecutive $\Delta$ Phe residues.

[^5]

Figure 6. Pentapeptide molecule showing helical sense without side chains.
These results might be of relevance to chemists and biochemists working in fields such as denovo peptide/protein design, conformational energy calculations, and design of peptide based drugs which are resistant to enzymatic degradation in vivo ${ }^{25}$ using amino acid residues such as $\Delta$ Phe.

Acknowledgment. The authors thank Prof. K. K. Tewari for continued encouragement, the Department of Science and Technology (DST), India for financial support, and the Department of Biotechnology (DBT), India for access to computers and graphic facilities at the Bioinformatics Center. We acknowledge with thanks the contribution of Dr. Y. Inai from the Nagoya Institute of Technology, Japan, for his invaluable help in carrying out the theoretical CD calculations and Dr. Vishwakarma from National Institute of Immunology, India for recording the mass spectrum of the title compound. K.R.R. thanks Council of Scientific and Industrial Research (CSIR), India for fellowship.
$\frac{\text { JA961460O }}{(25) \text { Jung, G. Angew. Chem. 1992, 104, } 1484 .}$


[^0]:    ${ }^{\dagger}$ Keywords: X-ray diffraction/ ${ }^{1} \mathrm{H}$ NMR/dehydropeptide/circular dichroism.
    ${ }^{\ddagger}$ International Centre for Genetic Engineering and Biotechnology. Telefax: 91-11-6862316.
    § Indian Institute of Science.
    $\perp$ Abbreviations: Peptide 1, Boc-L-Val- $\Delta$ Phe- $\Delta$ Phe- $\Delta$ Phe-L-Val-OMe; DL-Phe $(\beta-\mathrm{OH})-\mathrm{OH}, \mathrm{DL}-\beta$-phenylserine; $\Delta$ a.a, $\alpha, \beta$-dehydroamino acid; $\Delta \mathrm{Phe}$, $\alpha, \beta$-dehydrophenylalanine; NMR, nuclear magnetic resonance; ppm, parts per million; ROESY, rotating frame Overhauser spectroscopy; COSY, correlation spectroscopy; CD, circular dichroism; TLC, thin layer chromatography
    ${ }^{\otimes}$ Abstract published in Advance ACS Abstracts, March 15, 1997.
    (1) Jain, R. M.; Chauhan, V. S. Biopolymers (Peptide Science) 1996, 40, 105.
    (2) English, M. L.; Stammer, C. H. Biochem. Biophys. Res. Commun. 1978, 83, 1464.
    (3) (a) Kaur, P.; Patnaik, G. K.; Raghubir, R.; Chauhan, V. S. Bull. Chem. Soc. Jpn. 1992, 65, 3412. (b) Shimohigashi, Y.; English, M. L; Stammer, C. H.; Costa, T. Biochem. Biophys. Res. Commun. 1982, 104, 583.
    (4) Venkatachalam, C. M. Biopolymers 1968, 6, 1425.

[^1]:    (7) Sheldrick, G. M. Acta.Crystallogr. 1990, A46, 467.
    (8) (a) Aue, W. D.; Bartholdi, E.; Ernst, R. R. J. Chem. Phys. 1976, 64, 2229. (b) Bothner-By, A. A.; Stephens, R. L.; Lee, J.; Warren, C. D.; Jeanloz, R. W. J. Am. Chem. Soc. 1984, 106, 811-813.
    (9) Inai, Y.; Ito, T.; Hirabayashi, T.; Yokota, K. Biopolymers 1993, 33, 1173.
    (10) Benedetti, E. In Chemistry and Biochemistry of Amino Acids, Peptides and Proteins; Weinstein, B., Ed.; Dekker: New York, 1982, pp 105.

[^2]:    (13) (a) Benedetti, E.; Di Blasio, B.; Pavone, V.; Pedone, C.; Toniolo, C.; Crisma, M. Biopolymers 1992, 32, 453. (b) Toniolo, C.; Benedetti, E. Trends Biochem. Sci. 1991, 16, 350. (c) Barlow, D. J.; Thornton, J. M. J. Mol. Biol. 1988, 201, 601.
    (14) (a) Baker, E. N.; Hubbard, R. E. Prog. Biophys. Molec. Biol. 1984, 44, 97. (b) Richardson, J. S. Adv. Protein Chem. 1981, 34, 167.

[^3]:    (15) (a) Kessler, H. Angew Chem., Int. Ed. Engl. 1982, 21, 512. (b) Smith, J. A.; Pease, L. G. CRC Crit. Rev. Biochem. 1980, 8, 315.
    (16) Prasad, B. V. V.; Balaram, P. CRC Crit. Rev. Biochem. 1984, 16, 307.
    (17) Bothner-By, A. A.; Stephen, R. L.; Lee, J.; Warren, C. D.; Jeanlog, R. W. J. Am. Chem Soc. 1984, 106, 811.
    (18) (a) Rao, B. N. N.; Kumar, A.; Balaram, H.; Ravi, A.; Balaram, P. J. Am. Chem. Soc. 1983, 105, 74 23. (b) Wuthrich, K.; Billeter, M.; Braun, W. J. Mol. Biol. 1984, 180, 715.

[^4]:    (19) Basu, G.; Kuki, A. Biopolymers 1993, 33, 1173.

[^5]:    (24) (a) Aleman, C.; Perez, J. J. Biopolymers 1993, 33, 1811. (b) Aleman, C. Biopolymers 1994, 34, 841 .

